Literature DB >> 35181819

Fast clearance of anti-TNFα agents unrelated to antidrug antibodies: a case report.

Stefania Cheli1,2, Valeria Cozzi3, Dario Cattaneo3, Lorenzo Norsa4, Costantino De Giacomo5, Emilio Clementi6,7, Chiara Moretti5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35181819     DOI： 10.1007/s00228-022-03294-2

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  13 in total

1.  Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis.

Authors:  Gwan Gyu Song; Young Ho Seo; Jae-Hoon Kim; Sung Jae Choi; Jong Dae Ji; Young Ho Lee
Journal:  Pharmacogenomics       Date:  2015-08-05       Impact factor: 2.533

2.  Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease.

Authors:  Niels Vande Casteele; Marc Ferrante; Gert Van Assche; Vera Ballet; Griet Compernolle; Kristel Van Steen; Steven Simoens; Paul Rutgeerts; Ann Gils; Séverine Vermeire
Journal:  Gastroenterology       Date:  2015-02-24       Impact factor: 22.682

3.  Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review.

Authors:  Mario Regazzi; Joseè Golay; Mariadelfina Molinaro
Journal:  Ther Drug Monit       Date:  2020-02       Impact factor: 3.681

4.  Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?

Authors:  Konstantinos Papamichael; Adam S Cheifetz
Journal:  Curr Opin Gastroenterol       Date:  2019-07       Impact factor: 3.287

Review 5.  Optimizing anti-TNF treatments in inflammatory bowel disease.

Authors:  Shomron Ben-Horin; Uri Kopylov; Yehuda Chowers
Journal:  Autoimmun Rev       Date:  2013-06-19       Impact factor: 9.754

6.  Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease.

Authors:  Adam Frymoyer; Travis L Piester; K T Park
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-05       Impact factor: 2.839

7.  Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.

Authors:  Amit Assa; Manar Matar; Dan Turner; Efrat Broide; Batia Weiss; Oren Ledder; Anat Guz-Mark; Firas Rinawi; Shlomi Cohen; Chani Topf-Olivestone; Ron Shaoul; Baruch Yerushalmi; Raanan Shamir
Journal:  Gastroenterology       Date:  2019-06-10       Impact factor: 22.682

Review 8.  Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.

Authors:  J P Gisbert; A C Marín; A G McNicholl; M Chaparro
Journal:  Aliment Pharmacol Ther       Date:  2015-02-04       Impact factor: 8.171

9.  Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.

Authors:  Xavier Roblin; Hubert Marotte; Melanie Rinaudo; Emilie Del Tedesco; Amelie Moreau; Jean Marc Phelip; Christian Genin; Laurent Peyrin-Biroulet; Stephane Paul
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-23       Impact factor: 11.382

10.  Infliximab in young paediatric IBD patients: it is all about the dosing.

Authors:  Maria M E Jongsma; Dwight A Winter; Hien Q Huynh; Lorenzo Norsa; Seamus Hussey; Kaija-Leena Kolho; Jiri Bronsky; Amit Assa; Shlomi Cohen; Raffi Lev-Tzion; Stephanie Van Biervliet; Dimitris Rizopoulos; Tim G J de Meij; Dror S Shouval; Eytan Wine; Victorien M Wolters; Christine Martinez-Vinson; Lissy de Ridder
Journal:  Eur J Pediatr       Date:  2020-08-19       Impact factor: 3.183
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.